<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566863</url>
  </required_header>
  <id_info>
    <org_study_id>GUMed-Wu-003</org_study_id>
    <nct_id>NCT02566863</nct_id>
  </id_info>
  <brief_title>Haemodynamic Effect of Dexmedetomidine</brief_title>
  <official_title>Haemodynamic Effect of Dexmedetomidine in Relation to Autonomic System Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine, selective alfa2 receptors agonist produces sympatholysis. As a result heart&#xD;
      rate decreases. With low doses blood pressure also decreases, with higher dosing - systematic&#xD;
      vascular resistance increases. The indication for the drug is to produce sedation during&#xD;
      surgical procedures and in ICU patients.&#xD;
&#xD;
      The aim of a study is to verify, whether the haemodynamic effect (heart rate, blood pressure&#xD;
      and heart rate variability during drug infusion) depend on pre-drug autonomic system&#xD;
      activity. Autonomic system activity is assessed using heart rate variability (HRV)measurement&#xD;
      before drug injection and during drug infusion. Heart rate and blood pressure measured before&#xD;
      and during drug infusion will be analysed.&#xD;
&#xD;
      HRV measurement analysis will be based on continuous Holter ECG recording, taken before drug&#xD;
      injection and during its infusion. 5 minutes intervals will be analysed , using Frequency&#xD;
      Domain Measures of HRV. Surgical procedure will start after measurement have been taken.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of haemodynamics and heart rate variability parameters</measure>
    <time_frame>up to 30 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Haemodynamic Effects of Dexmedetomidine</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine, 1 mcg/kg over 10 minutes, followed by a maintenance infusion, given to achieve sedation for eye surgery procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor</other_name>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients classified with American Society of Anesthesiologists Physical Status&#xD;
             Classification System as 1 or 2 status&#xD;
&#xD;
          -  planned eye surgery under sedation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient's refusal&#xD;
&#xD;
          -  contraindications to dexmedetomidine&#xD;
&#xD;
          -  diseases/drugs that influence on autonomic nervous system activity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena A Wujtewicz, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Medical University of Gda≈Ñsk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Magdalena Wujtewicz</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>heart rate</keyword>
  <keyword>heart rate variability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

